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Prion-like propagation of tau aggregation might un-
derlie the stereotyped progression of neurodegener-
ative tauopathies. True prions stably maintain unique
conformations (‘‘strains’’) in vivo that link structure
to patterns of pathology. We now find that tau meets
this criterion. Stably expressed tau repeat domain
indefinitely propagates distinct amyloid conforma-
tions in a clonal fashion in culture. Reintroduction
of tau from these lines into naive cells reestablishes
identical clones. We produced two strains in vitro
that induce distinct pathologies in vivo as deter-
mined by successive inoculations into three genera-
tions of transgenic mice. Immunopurified tau from
these mice recreates the original strains in culture.
We used the cell system to isolate tau strains from
29 patients with 5 different tauopathies, finding that
different diseases are associated with different sets
of strains. Tau thus demonstrates essential charac-
teristics of a prion. This might explain the phenotypic
diversity of tauopathies and could enablemore effec-
tive diagnosis and therapy.
INTRODUCTION
Tauopathies are a diverse group of neurodegenerative diseases
defined by accumulation of fibrillar deposits of the microtubule-
associated protein tau (MAPT) (Lee et al., 2001). Alzheimer’s
disease (AD), the most common tauopathy, affects >30 million
people worldwide and will afflict >120 million by 2050 (Holtzman
et al., 2011). MAPT mutations cause dominantly inherited tauo-
pathies (Hutton et al., 1998) and most increase the propensity
of tau to form amyloids (Barghorn et al., 2000), which are para-
crystalline protein assemblies rich in beta-sheet structure (Bonar
et al., 1969). Most tauopathy cases are sporadic, with variable
clinical and pathological presentation (Lee et al., 2001).
The prion hypothesis posits that pathological aggregates of
the mammalian prion protein (PrP) cause infectious, sporadic,and familial neurodegenerative diseases (Prusiner, 1998). In
contrast, yeast prions are adaptive and confer phenotypic diver-
sity and rapid evolution of new traits in times of stress (True and
Lindquist, 2000). Both yeast andmammalian prions form strains,
which are encoded by distinct fibrillar structures (Safar et al.,
1998; Toyama et al., 2007). Prion strains determine the incuba-
tion periods of disease in humans (Kim et al., 2012) and mice
(Legname et al., 2006). In addition, human prion strains are
thought to underlie clinical symptoms and pathological presen-
tation (Collinge and Clarke, 2007).
The hypothesis that common neurodegenerative diseases
such as AD could be caused by a prion-likemechanismwas sug-
gested three decades ago (Prusiner, 1984). Recently, however,
experimental work on diverse amyloids has generated new inter-
est (Frost and Diamond, 2010; Guo and Lee, 2014). Human
neurodegenerative diseases target unique neural networks
(Braak and Braak, 1995; Seeley et al., 2009), an observation
most parsimoniously explained by the network-based spread
of a toxic agent (Raj et al., 2012; Zhou et al., 2012). Prior studies
suggest that tau aggregates spread among cells via templated
conformational change (Frost et al., 2009a; Holmes et al.,
2013). In vivo work supports this model (Clavaguera et al.,
2009; de Calignon et al., 2012; Iba et al., 2013; Kim et al., 2010;
Liu et al., 2012) as has similar work with other intracellular amy-
loids such as a-synuclein (Desplats et al., 2009; Luk et al.,
2012) and extracellular amyloids including amyloid b (Meyer-
Luehmann et al., 2006).
Bona fide prions are defined by propagation of distinct confor-
mational strains in vivo, and prior studies have hinted at prion-
like strain properties of non-PrP human amyloids. For example,
amyloid b protein forms at least two distinct, self-propagating
fibrillar conformations in vitro (Petkova et al., 2005) and in vivo
(Lu et al., 2013). Others have demonstrated propagation
in vitro of distinct tau (Frost et al., 2009b; Siddiqua andMargittai,
2010) and a-synuclein conformers (Bousset et al., 2013; Guo
et al., 2013; Sacino et al., 2013). While provocative, these prior
studies have not demonstrated that noninfectious proteopathic
seeds act as true prions. Specifically, it has not been shown
that distinct conformations or ‘‘strains’’ are capable of transmis-
sion into a living cell or organism, propagation through multiple
generations, extraction, and reintroduction to naive cells or or-
ganisms to replicate the same structural phenotype (CollingeNeuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc. 1271
αSyn
Ta
u
 R
D
-Y
FP
H
tt 
Q2
5-
YF
P
α
Sy
n-
YF
P
WT 2P ΔK280 LM
Bu
ffe
r
Fi
br
ils
A
DC
B
E F
0 10 20 30 40 50
0
10
20
30
40
Days Post-Treatment
%
 C
ell
s 
w
ith
 
I n
clu
sio
ns
20 30 40 50
0
2
4
6
8
10 400 nM Fibrils
Buffer
Contains 
Inclusions
=
Buffer Aβ Htt Tau RD
Transduced Fibrils
Tr
a
n
sd
uc
ed
 R
ea
ge
nt
Stable Tau RD-YFP Cell Line
St
ab
le
 C
el
l L
in
e
Figure 1. Homotypic Seeding Produces
Stably Propagated Tau RD Inclusions
(A) Polyclonal HEK293 lines stably expres-
sing YFP-tagged tau RD, a-synuclein, or htt
exon1(Q25) were transduced with buffer, or fibrils
of Ab, Htt, a-syn, or tau RD. Cells were DAPI-
stained on day 6. Only homotypic seeding
occurred. See Figure S1A for construct diagrams,
Figure S1B for quantification, and Figures S1C and
S1D for similar homotypic seeding with full-length
(FL) 4R1N tau P301S.
(B) Polyclonal HEK293 lines stably expressing
tau RD-YFP with no mutations (WT), DK280
(proaggregation), DK280/I277P/I308P (2P; anti-
aggregation), or P301L/V337M (LM; proag-
gregation) were transduced with either buffer or
tau RD fibrils. Upon fibril transduction, all form
inclusions, except for 2P.
(C) Tau RD(LM)-YFP cells transduced with either
buffer or tau RD fibrils were passaged every two
days. On every other passage, the percentage of
cells with inclusions was quantified (n = 10 fields,
each with 150+ cells per condition). Inset high-
lights inclusion-positive cells at later time points.
Error bars represent SEM.
(D) At day 50 following exposure to fibrils, inclu-
sion-positive cells were visible.
(E and F) At day 3 following exposure to fibrils, tau
RD(LM)-YFP cells were diluted sparsely on cov-
erslips and grown for 8 days. Colonies were either
100% inclusion-negative (E) or 100% inclusion-
positive (F).
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Tau Prion Strains in Cells, Mice, and PatientsandClarke, 2007). This is important not for semantic reasons, but
because if prion mechanisms underlie human disease, only sta-
bly propagating strains can account for stereotyped clinical pre-
sentation and network spread. In this study, we have found that
tau acts as a prion by these criteria, and, further, that individual
human tauopathies are associated with unique strains.
RESULTS
Homotypic Seeding of Tau Depends on Beta-Sheet
Structure
Amino acid sequence disparities impair cross-seeding between
PrP moieties from different species, leading to ‘‘seeding
barriers’’ (Collinge and Clarke, 2007). To test the fidelity of het-
ero- versus homotypic seeding for tau, we expressed several
amyloidogenic proteins and exposed them to a variety of fibrillar
seeds. Prolonged expression of full-length (FL) tau can be toxic
to dividing cells. Thus for tau, we expressed the aggregation-1272 Neuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc.competent core, termed the repeat
domain (tau RD; aa 244–372 of the 441
aa FL tau 4R2N) (Wischik et al., 1988).
We generated polyclonal HEK293 cell
lines stably expressing tau RD-YFP,
a-synuclein-YFP, or huntingtin (htt) exon
1(Q25)-YFP (see Figure S1A for construct
diagrams). Inclusions did not occur in any
line without exposure to exogenous fi-brils. However, upon transduction of fibrils (Ab [1–42], htt exon
1 N17[Q35], a-synuclein, tau RD) with liposomes, we observed
homotypic but not heterotypic seeding for each amyloidogenic
protein (Figure 1A; Figure S1B for quantification), consistent
with sequence-specific templating. Prior reports have indicated
that in certain cases, a-synuclein aggregates can cross-seed FL
tau (Giasson et al., 2003; Guo et al., 2013;Waxman and Giasson,
2011). Thus, we tested this for both YFP-tagged and untagged
versions of FL tau 4R1N P301S. We observed only homotypic
seeding and no cross-seeding of tau by a-synuclein or any
other amyloid (Figures S1C and S1D). This is consistent with
sequence-specific templating, although we cannot rule out
the possibility that different amyloid conformers are capable of
heterologous seeding, as has previously been reported (Guo
et al., 2013).
Amyloids typically feature a cross beta-sheet conformation
(Bonar et al., 1969). We exploited two proline substitutions
(I277P/I308P) in tau that block its ability to enter into this
Neuron
Tau Prion Strains in Cells, Mice, and Patientsquaternary form (von Bergen et al., 2001) to test whether inclu-
sion formation requires this property. Polyclonal HEK293 cell
lines stably expressing tau RD-YFP with no mutations (wild-
type, WT), P301L/V337M (LM: proaggregation), DK280 (proag-
gregation), or DK280/I277P/I308P (2P: antiaggregation) were
transduced with tau RD fibrils. All formed inclusions except tau
RD(2P)-YFP, confirming that beta-sheet structure is required
for tau RD inclusion formation in our model system (Figure 1B).
Stable Inheritance of Tau RD Aggregates
Seeded htt exon 1 (Ren et al., 2009), Sup35NM (Krammer et al.,
2009), SOD1 (Mu¨nch et al., 2011), and a-synuclein (Bousset
et al., 2013) form persistent intracellular inclusions in cultured
cells. We tested this for tau RD. We transduced tau RD fibrils
or buffer into polyclonal tau RD(LM)-YFP (hereafter, referred to
as tau RD) cells, chosen for their superior ability to be seeded
relative to tau RD(WT)-YFP, and quantified the percentage of
cells with inclusions on every other passage. Transduced fibrils
induced tau RD inclusions that persisted >50 days postexposure
(Figure 1C). We hypothesized that the aggregated state was sta-
bly inherited because inclusion-containing cells formed local
clusters (Figure 1D). To test this, we sparsely diluted fibril-trans-
duced tau RD cells to isolate individual colonies. These were
composed of either 100% inclusion-negative (Figure 1E) or
100% inclusion-positive (Figure 1F) cells, indicating stable inher-
itance of the aggregated state.
Tau RD Propagates Conformationally Distinct Strains
Only prion protein (PrP) (Birkett et al., 2001) and certain fungal
prions (e.g., Sup35 [PSI+]) (Derkatch et al., 1996) unequivocally
propagate distinct conformational states, or strains, in cell cul-
ture. To test the ability of tau RD to propagate distinct con-
formers, we diluted fibril-transduced monoclonal tau RD cells
and isolated individual clones that stably propagated inclusions
(Figure 2A). Previous work with the Sup35 protein has indicated
that inclusion morphology is a proxy for biochemically distinct
yeast prion strains in dividing mammalian cells (Krammer
et al., 2009). We thus characterized 20 tau RD clones based on
inclusion morphology, numbered in order of isolation. Most
(Figure S2A) featured small juxtanuclear inclusions with many
nuclear speckles, exemplified by clone 9 (Figure 2B). Clone 10
alone propagated a single, large juxtanuclear inclusion (Fig-
ure 2B). We confirmed that stably propagated tau RD inclusions
were amyloids as clones 9 and 10, but not inclusion-negative
clone 1, bound X-34, a Congo red derivative that stains beta-
sheet structures (Figure 2C).
To characterize the clones biochemically, we first used semi-
denaturing detergent agarose gel electrophoresis (SDD-AGE), a
method that differentiates strains based on aggregate size (Kryn-
dushkin et al., 2003). Tau RD species from clone 10 were larger
than those propagated by clone 9 (Figure 2D). Thus, the clone 10
fibrils might not be as readily fragmented into smaller species
(Tanaka et al., 2006). Next, we used sedimentation analysis to
differentiate the strains (Tanaka et al., 2006). Clone 1 had entirely
soluble tau RD, whereas clones 9 and 10 had insoluble tau RD
(Figure 2E). Clone 10 featured more soluble tau RD than clone
9. To probe for structural differences, we used limited proteolysis
as has been used previously for differentiating PrP conformers(Bessen and Marsh, 1994). Cell lines propagating aggregates
(clones 9, 10) featured pronase-resistant species between 10
and 13 kDa, as well as between 20 and 25 kDa in size (Figure 2F).
Clone 9 produced a smear between 10 and 13 kDa, whereas
clone 10 produced a clear doublet. These studies indicated clear
differences in biochemical characteristics of the clones, consis-
tent with distinct strain conformations.
Prion strains often have different seeding efficiencies, which
can result in variable incubation times in vivo (Legname et al.,
2006). Thus we compared the clones, modifying a preexisting
split-luciferase complementation assay (Naik and Piwnica-
Worms, 2007) for use as a tau aggregation sensor (Figure S1A).
Clone 1 contained no seeding activity. However, inclusion-con-
taining lines seeded robustly, especially clone 9, which seeded
more than clone 10 (Figure 2G). Differences in seeding were
not an artifact of cell confluency, as determined by normalizing
to cell number in seeding experiments (Figure S2B).
Next, we compared the toxicities of clones 9 and 10. Although
clone 9 lysate initially seeded a greater number of cells, these
were rapidly eliminated relative to those induced by clone 10
(Figure 2H). Furthermore, cells containing clone 9-derived inclu-
sions grew more slowly than those derived from clone 10 (Fig-
ure 2I). Whereas growth rate of nontransfected HEK293 cells
was not affected by inoculation with clone 9 lysate, growth of
tau RD cells was impaired following the same treatment (Fig-
ure S2C). This was not seen for clone 10. Finally, an LDH assay
suggested that clone 9 lysate is toxic to tau RD cells relative to a
sham treatment (Figure S2D).
A previous study reported that tau from human brain can
induce aggresome structures in vitro (Santa-Maria et al., 2012).
Thus, we examined the subcellular localization of inclusions
associated with clones 9 and 10. Based on antivimentin stains
(Figure S2E), electron microscopy (Figure S2F), and anti-g-
tubulin stains (Figure S2G), we conclude that juxtanuclear clone
10 inclusions are canonical aggresomes, unlike the inclusions of
clone 9. Intranuclear clone 9 inclusions did not colocalize with
PML bodies (Figure S2H). Thus, clones 9 and 10 propagate con-
formationally distinct tau prion strains, with different conse-
quences for the cell. To test the fidelity of strain inheritance,
we passaged them continuously for 6 months. Inclusion mor-
phologies (Figure 2J) and limited proteolysis patterns (Figure 2K)
associated with clones 9 and 10 were unaltered. Thus, tau RD
prion strains are robust, maintaining their phenotypes indefinitely
in cell culture.
Transfer of Strain Phenotype to Naive Cells
To rule out an effect of cell background on strain formation, we
transduced clone 9 and 10 lysates into naive monoclonal tau
RD cells, isolating 6 colonies (A–F) for each (Figure 3A). We eval-
uated derivative clones (9C was lost in passage) by inclusion
morphology (Figure 3B), SDD-AGE (Figure 3C), sedimentation
analyses (Figure 3D; Figure S3B), seeding activity (Figure 3E),
and limited proteolysis (Figure 3F). In all cases, derivative clones
matched their associated progenitors, indicating that tau RD
prion strains are encoded by conformation, independent of cell
background. Faithful templating into naive cells also occurred
after passive addition of lysates to media (Figure S3A), thus indi-
cating that bypassing physiological uptake is not necessary forNeuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc. 1273
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Figure 2. Generation of Stably Inherited Tau RD Prion Strains
(A) A monoclonal HEK293 line stably expressing tau RD(LM)-YFP (hereafter referred to as tau RD) was transduced with tau RD fibrils. At day 3, cells were diluted
sparsely in a 10 cmdish. At day 12, inclusion-positive colonieswere identified and picked, amplifying to confluency in separate 10 cmdishes. At day 30, cells were
replated for confocal analysis or harvested for subsequent experiments.
(B) Confocal analysis of morphologically distinct tau RD prion strains. Clone 1 does not contain inclusions. Clone 9 contains nuclear speckles and a small
juxtanuclear inclusion. Clone 10 features one very large juxtanuclear inclusion and no nuclear speckles. See Figure S2A for other clones.
(C) Clones 1, 9, and 10 were stained with X-34, an amyloid dye. X-34 staining is only observed in clone 9 and clone 10, indicating that the propagated aggregates
are amyloids.
(legend continued on next page)
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Tau Prion Strains in Cells, Mice, and Patientstemplating. With a Tet Off line to control tau RD expression, we
demonstrated that the aggregate-positive phenotype can be
cured by stopping expression for 7 days and then restarting it
(Figures S3C and S3D).
To rule out an artifact of using artificial truncated tau RD and
dividing cell model systems, we examined FL tau inclusion for-
mation in primary cortical neurons. Neurons expressing FL tau
P301S-YFP formed detergent-resistant inclusions following
treatment with clone 9 or 10, but not clone 1 or PBS (Figure 3G).
Clone 9 seeded very robustly relative to clone 10 (Figure S3E).
Clone 9 lysate created inclusions throughout the soma and pro-
cesses of neurons with untagged and YFP-tagged FL P301S tau,
whereas clone 10 lysate primarily seeded inclusion bodies
confined to the soma (Figure 3G; Figures S3F and S3G). Corrob-
orating prior studies (Aoyagi et al., 2007; Miyasaka et al., 2001),
we observed a seeding barrier between WT tau and P301 mu-
tants (P301L, P301S). Specifically, aggregates from clones 9
and 10, which feature both the P301L and V337M mutations,
never seeded aggregation in neurons expressing FL tau WT-
YFP (Figure 3H) and FL tau WT (no tag) (data not shown). This
seeding barrier was confirmed to be asymmetric by using a panel
of split-luciferase tau RD mutant pairs (Figure S3H), which
demonstrated that WT tau RD can seed all forms of RD (WT,
P301L, P301S, P301L/V337M), whereas P301 mutants cannot
seed WT.
Tau Strains Induce Unique Pathologies in Transgenic
Tau P301S Mice
Inoculation of recombinant fibrils into transgenic P301S mice
(Yoshiyama et al., 2007), which express a form of mutant tau
associated with dominantly inherited tauopathy, rapidly induces
pathology within weeks (Iba et al., 2013). Thus, we tested
whether tau strains formed in cell culture would have similar ef-
fects. We inoculated equivalent amounts of lysate from clones
1, 9, and 10, as well as recombinant tau RD fibrils (RF), bilaterally
into the hippocampi of 3-month-old mice (Figure 4A). For all ex-
periments, conditions were gender matched (Table S1). After
3 weeks, RFs induced tangle-like pathology when assessed by
AT8 (Figures 4B and 4C), an antibody against FL phospho-tau,
as previously reported (Iba et al., 2013). Clones 9 and 10 induced(D) SDD-AGE demonstrates that clone 10 features larger aggregates than clone
(E) Sedimentation analysis was performed on clones 1, 9, and 10. Pellet (P) w
supernatant was loaded at a 3:1 ratio to pellet and total (T) to allow clear detection
has almost all tau RD in the pellet. Clone 10 has mixed solubility.
(F) Limited proteolysis (pronase) digests all tau RD in clone 1 but reveals protease
25 kDa in clone 9 and 10. Unlike clone 9, clone 10 digestion produces a doublet
(G) A split-luciferase assay reports differential seeding efficiency of tau RD prion s
was transduced with lysate from the three clones. Clone 1 does not seed agg
Averages of four separate experiments are shown, each read in quadruplicate 4
Figure S2B for evidence that differences in cell confluency do not account for di
(H) Inclusion elimination rates differ between clones. After transduction with lysate
on days 4, 17, and 30 (n = 10 fields, each with 150+ cells per condition). Cells with i
Error bars represent SEM, **** = p < 0.0001.
(I) Clone 9-transduced cells growmore slowly. After transduction of stable cells, c
inclusions derived from clone 10. Colonies without inclusions have identical ce
differences in cell growth rate in tau RD(LM)-HA cells and Figure S2D for LDH to
(J) Clones 1, 9, and 10maintain distinctive morphologies after 6 months in culture.
clone 9, inclusions are aggresomes.
(K) Structural characteristics (limited proteolysis digestion patterns) of strains areunique pathologies, whereas clone 1 did not cause any detect-
able abnormality (Figures 4C and 4D). Whereas clone 9 induced
tangle-like inclusions throughout CA1 and CA3, clone 10
induced AT8-positive puncta in mossy fiber tracts (Figure 4D).
Staining with MC1, an antibody against conformationally-altered
tau (Jicha et al., 1997), confirmed these differences (Figure S4A).
X-34, an amyloid dye, primarily recognized clone 9 pathology
(Figure S4A), although light staining was observed in CA1 of
clone 10-inoculated mice. Pathological differences could not
be explained by differences in the amount of total or insoluble
tau RD inoculated (Figures S4E and S4F). Injected WT mice
never developed pathology (Figure S4B), possibly due to a seed-
ing barrier between inoculated tau RD and WT murine tau (Fig-
ure 3H; Figures S3E and S3H).
P301S mice inoculated with clone 10 uniquely accumulated
elongated Iba1-positive rod microglia (Figure 4E), which aligned
end-to-end parallel to CA1 pyramidal axons (Figure S4C). Such
unique coupling of rod microglia has been observed in a rodent
traumatic-brain-injury model and might be protective for injured
axons (Ziebell et al., 2012).WTmice inoculated with clones 9 and
10 did not feature this pathology, indicating that endogenous hu-
man P301S tau is required for this induced microglial phenotype
(Figure S4D).
Tau Strains Are Stably Propagated through Multiple
Generations in Mice
Prions can be stably passaged in vivo (Bruce et al., 1994). Thus,
we performed serial inoculation of brain homogenates into naive
P301S mice (Figure 5A). Brain homogenate from WT or P301S
mice inoculated with clones 1, 9, or 10 (termed generation G0)
was inoculated into naive P301S mice (generation G1). After
28 days, brains were collected for histology and biochemistry,
and the process was repeated in a second round of P301S
mice (generation G2). Immunohistochemistry demonstrated
identical pathology for each generation of mice: clone 9 serial
propagation induced AT8-positive, tangle-like pathology in
CA1 and CA3 regions, whereas clone 10 serial propagation
induced AT8-positive puncta in the mossy fiber tracts of the
hippocampus (Figures 5B and 5C; Figure S5A). Clone 1 induced
no pathology in any generation (Figure 5B; Figure S5B).9.
as isolated from supernatant (S) by ultracentrifugation. For clones 9 and 10,
; clone 1, a 1:1 ratio. Clone 1 has all tau RD in the supernatant, whereas clone 9
-resistant tau RD peptides between 10 and 13 kDa, as well as between 20 and
, consistent with a distinct conformation.
trains. A polyclonal HEK293 line expressing both tau RD-CLuc and tau RD-Nluc
regation. Clone 9 seeds robustly, whereas clone 10 seeds significantly less.
8 hr posttransduction (error bars = S.E.M, * = p < 0.05, **** = p < 0.0001). See
fferences in luminescence.
from clone 9 or 10, the percentage of cells containing inclusions was quantified
nclusions derived from clone 9 are eliminated more rapidly from the population.
olonies with inclusions derived from clone 9 have fewer cells than colonies with
ll numbers (error bars represent SEM, **** = p < 0.0001). See Figure S2C for
xicity assay in tau RD(LM)-HA background.
See also Figure S2E–S2H for data indicating that juxtanuclear clone 10, but not
propagated with high fidelity over 6 months.
Neuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc. 1275
A B
E
G H
F
 1      9      10      9A    10A    9B   10B    10C     9D    10D    9E   10E    9F   10F
10
15
20
25
MW (kDa) 
Re
la
tiv
e 
Lu
m
in
es
ce
nc
e
FL
 
Ta
u
 P
30
1S
-Y
FP
 
 
 
(T
X-
Ex
tra
cte
d)
1 9 9A 9B 9D 9E 9F 1010
A
10
B
10
C
10
D
10
E
10
F
0
5
10
15
20
25
1
2
2
2
2
2
2
           Clone 1             Clone 9      Clone 10D
     T       S       P        T        S       P       T        S       P
C
1   9  10  9A 10A 9B 10B 10C      1   9  10   9D 10D 9E 10E 9F 10F
M
onom
er
s
et
a
ge
r
g g
A
Clone 1 Clone 10A Clone 10BClone 9A
Clone 9B Clone 9D
Clone 9FClone 9E
Clone 10C Clone 10D
Clone 10E Clone 10F
ns
ns
****
Lysate          
Transduction 
(Day 0)
Boil and Clarify 
Lysate         
(Day 0)
Dilution         
(Day 3)
Colony selection  
and amplification  
(Day 12)
 Clone 9  Clone 10
+ +
Liposomes
PBS Clone 1 Clone 9 Clone 10 Clone 9 Clone 10
FL
 
Ta
u
 W
T-
YF
P
 
(T
X-
Ex
tra
cte
d)
A
B
C
D
E
F
Figure 3. Tau RD Aggregates Transfer Strain Conformations into Naive Cells
(A) Lysates from clones 9 and 10 were transduced into naive tau RD-YFP cells and monoclonal inclusion-containing cells were isolated and amplified. Six
secondary clones were generated for each condition, but one (clone 9C) failed to amplify.
(B) Morphologies of primary clones are maintained in secondary cell lines. See also Figure S3A, which demonstrates that this templating of morphology is not
dependent on liposome-mediated transduction of lysate.
(legend continued on next page)
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Tau Prion Strains in Cells, Mice, and PatientsHomogenate from WT mice inoculated with the original cell tau
strains (G0) did not produce pathology upon passage into
P301S mice (Figure S5C). Therefore, pathology observed in G1
and G2 cannot be due to residual tau RD seeds from the original
inoculum, and tau prions propagate unique phenotypes for mul-
tiple passages in vivo.
In Vivo Tau Strains Maintain Phenotypes upon Passage
back into Cells
To conclusively test whether tau strains are biochemically stable
after passage in vivo, we isolated FL P301S tau from micro-
dissected hippocampi of injected mice (G0) by using a mono-
clonal antibody (HJ8.5) that binds an epitope present in FL tau,
but not tau RD (Yanamandra et al., 2013). We assessed seeding
activity in G0 samples by split-luciferase complementation and
inclusion counts. Only hippocampi from P301S mice (G0) in-
jected with tau RD aggregates contained seeding activity (Fig-
ure 6A; Figure S6A). This did not correlate with the amount of
immunoprecipitated tau (Figure S6D). WT mouse hippocampi
never seeded, regardless of the inoculum. We next tested
whether the strains introduced into G0 mice could be reisolated
in tau RD cells. Scoring of single colonies based on morphology
(containing or lacking nuclear speckles) suggested that strains
were unaltered following a single passage through mice (Figures
S6B and S6C). To further confirm this, we blindly selected and
amplified a single representative colony associated with each
mouse. All G0-clone 9 and G0-clone 10 samples recapitulated
the morphologies of the original clones 9 and 10 (Figure 6B).
Limited proteolysis patterns (Figure 6C) and seeding propen-
sities were also identical (Figure 6D).
Similar experiments were performed following the third pas-
sage (G2). Immunoprecipitated (IP) tau from pooled G2-clone 9
and G2-clone 10 homogenates seeded far more strongly than
G2-clone 1 homogenates (Figure 6E). Immunoglobulin G (IgG)-
precipitated material did not seed (Figure 6E; Figure S6E), and
IP tau seeded as strongly as crude homogenate in a split-lucif-
erase assay (Figure S6E). Tau alone thus accounts for the seed-
ing activity reported in these assays.
Next, we introduced IP material from G2 mice into tau RD re-
porter cells and scored colonies based on morphology prior to
isolation of monoclonal lines. G2-clone 9 colonies almost exclu-
sively featured nuclear inclusions, whereas virtually all G2-clone
10 colonies lacked them (Figure S6F). The rare inclusion-positive
colonies associated with G2-clone 1 also featured nuclear inclu-(C) SDD-AGE of lysates from both primary and secondary clones demonstrates s
separates gels run separately.
(D) Sedimentation analysis was performed as described in Figure 2E. Secondary c
derived. For original blots, see Figure S3B.
(E) Split-luciferase complementation demonstrates similar seeding efficiencies in
are shown, each read in quadruplicate 48 hr posttransduction of lysate (error ba
(F) Limited proteolysis shows that all clone 10 derivatives feature a doublet wherea
13 kDa. Clone 9 derivatives feature a more resistant band between 20 and 25 kD
(G) Lysates from clones 9 and 10, but not clone 1, induce detergent-resistant F
neurons. Clone 9 induces tangle-like structures throughout the soma and neuritic
Figure S3E for data showing that clone 9 seedsmore widespread inclusion formati
and Figure S3G for images of tangles throughout processes of clone 9-inoculate
(H) Clone 9 and clone 10 lysates containing tau RD(P301L/V337M)-YFP, do not see
due to an asymmetric seeding barrier between FL tau with and without P301 musions, which suggested that some of the G2-clone 10 colonies
containing nuclear inclusions could arise from an intrinsic
P301S-derived strain. Monoclonal strains (n = 12) were blindly
selected for each G2 cohort. In all but one case (G2-clone
10D), inclusion morphologies matched that of the original inocu-
late (Figure 6F; Figure S6G). For both clone 9 and 10 cohorts, 11
of 12 clones matched their parental counterpart based on both
limited proteolysis (Figure 6G) and seeding activity (Figure 6H).
Intriguingly, the two outliers (G2-clone 9G, G2-clone 10D) had
identical proteolysis patterns and seeding ratios, which were
unique from those of all other clones. We speculate that these
clones result from an intrinsic strain within 4-month-old P301S
mice. We conclude that tau prion strains are stable across
numerous passages through cells and animals.
Spread of Tau Pathology to Distant, Synaptically
Connected Regions
After inoculation with recombinant tau fibrils, pathology can
develop in synaptically connected regions (Iba et al., 2013).
Our preliminary observations indicated that serial inoculations
with clone 9 induced pathology in the ipsilateral entorhinal cortex
(EC) (data not shown). To test for spread, we performed a final
inoculation (G3) into the left hippocampus of P301S mice. After
five weeks, G3-clone 9 mice had AT8-positive pathology in
regions that project to or from the hippocampus (Figure 7A)
including ipsilateral and contralateral EC, retrosplenial cortex
(RSp), and contralateral hippocampus (Figure 7B–7D; Fig-
ure S7A) (Andersen, 2007; van Groen et al., 2003). Ipsilateral
EC had robust pathology in layers II/III, whereas contralateral
EC pathology occurred in deeper cortical layers, suggesting
spread along defined anatomical connections (van Groen
et al., 2003). Furthermore, pathology was observed in ipsilateral
subiculum and dentate gyrus (Figure S7B). In contrast, G3-clone
1 brain did not show AT8-positivity above baseline (Figures 7B
and 7D). Overt spread was not observed in G3-clone 10 mice
(data not shown), perhaps due to its decreased seeding ability
(Figure 2G; Figure S3E). A heatmap summarizes the brain re-
gions with enhanced AT8-positive pathology in G3-clone 9
mice (Figure 7C). These results agree with previous work sug-
gesting that seeded intracellular amyloids spread along discrete
neural networks (de Calignon et al., 2012; Iba et al., 2013; Liu
et al., 2012; Luk et al., 2012; Zhou et al., 2012). We cannot
completely exclude the possibility that this was due to trans-syn-
aptic spread of inoculum.imilar aggregate sizes in secondary clones relative to the primary ones. A line
lones feature similar sedimentation patterns to the clones fromwhich they were
secondary lines versus parental lines. Averages of four separate experiments
rs represent SEM, **** = p < 0.0001).
s clone 9 derivatives are associated with an unresolvable band between 10 and
a. See Figures S3C and S3D for reversibility of aggregated state.
L tau P301S-YFP species, which colocalize with AT8 (red) in primary cortical
processes. Clone 10 primarily seeds punctate-like structures in the soma. See
on, Figure S3F for similar results in neurons expressing untagged FL tau P301S,
d neurons.
d inclusion formation in neurons expressingWT FL tau. For evidence that this is
tations, see Figure S3H.
Neuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc. 1277
Clone 1 Clone 9 Clone 10
Clarify Lysate
(Day 0)
Inject Lysate
(Day 0)
Collect Brain
for Histology
(Day 21)
A B C
P3
01
S 
R
F
E
D
P3
01
S 
C
lo
ne
 1
P3
01
S 
C
lo
ne
 9
P3
01
S 
C
lo
ne
 1
0
Hippocampus CA3 0µm CA3 +10µm
0
10
20
30
40
50
60
70
P301S
Ce
lls
 w
ith
AT
8 T
an
gl
e-
Li
ke
 P
os
iti
vit
y
Cl
on
e 1
Cl
on
e 9
Cl
on
e 1
0
Cl
on
e 1
Cl
on
e 9
Cl
on
e 1
0
RF
C
A
1 
Ib
a1
 
P301S Clone 10P301S Clone 1 P301S Clone 9
WT
AT8 IF
**
***
Figure 4. Clone 9 and 10 Induce Unique Tau and Microglia Pathology in P301S Mice
(A) Lysates (10 mg total protein) were injected bilaterally into the hippocampi of 3 month P301S and WT mice. At 21 days postinjection, left hemispheres were
collected for histology and right hemispheres for homogenization. See Table S1 for description of mice used in all experiments.
(B) Recombinant tau RD fibrils (RF) induce tangle-like, AT8-positive tau pathology near the injection site in CA1 (scale bars represent hippocampus – 1 mm and
inset – 100 mm).
(legend continued on next page)
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the Tauopathies
It has been hypothesized that conformationally distinct tau prion
strains might be associated with individual tauopathies (Clava-
guera et al., 2013b; Frost and Diamond, 2010), and a recent
study found that inoculation of transgenic human tau mice with
brain homogenates from patients with different tauopathies re-
capitulates certain pathological features of the diseases (Clava-
guera et al., 2013a). To examine whether inclusionmorphology is
a reasonable indicator of distinct strains, we first used our cell
model to examine brain homogenates from three individuals
with clinically distinct, pathologically verified tauopathies (all pa-
tient samples obtained from the Neurodegenerative Disease
Brain Bank at UCSF): Alzheimer’s disease (AD), corticobasal
degeneration (CBD), and argyrophilic grain disease (AGD). We
transduced IP or crude (CR) homogenate into the monoclonal
Tet Off HEK293 cell line (Figure 8A), used for its relatively high
tau RD expression and greater seeding efficacy, and charac-
terized resulting colonies morphologically and biochemically
(Figures S8A–S8I). Each brain induced a unique inclusion
morphology, independent of the transduction method (IP versus
CR) (Figures S8A–S8D). By analyzing three representative clones
derived from each brain by sedimentation analysis (Figure S8E),
seeding (Figures S8F and S8G), and limited proteolysis (Figures
S8H and S8I), we concluded that morphology reliably differenti-
ates biochemically distinct strains. Next, we expanded our anal-
ysis to include IP tau from patients with AD (n = 6), AGD (n = 6),
CBD (n = 6), Pick’s disease (PiD, n = 5), and progressive supra-
nuclear palsy (PSP; n = 6) (Table S2). Excepting PiD, a three-
repeat tauopathy, these are predominantly four-repeat (AGD,
CBD, PSP) or mixed-repeat (AD) tauopathies that differ in the
morphology and distribution of neuronal and glial tau inclusions
(Lee et al., 2001). We transduced IP tau from each sample into
the monoclonal Tet Off cell line and isolated clones with inclu-
sions (Figure 8A). We identified six morphological phenotypes
as follows: (1) no seeding, (2) toxic (all cells with inclusions
died and clones could not be isolated), (3) mosaic (unstable prion
strain), (4) ordered, (5) disordered, and (6) speckles (Figure 8B).
We blindly scored all clones based on tau RD inclusion
morphology. This revealed distinct strain compositions across
the diseases (Figure 8C). AD patient samples revealed remark-
able homogeneity, suggesting a predominant strain. Other
disorders revealed interpatient variation. Some patients featured
homogeneous strain composition (e.g., certain patients with
AGD, PSP), whereas others exhibited considerable heterogene-
ity. With few exceptions (e.g., AD1-AD4, AGD2, CBD5, PiD3),
most patient samples produced two or more strains. The range(C) Quantification of tangle-like, AT8-positive cell bodies within the hippocampus
have significantlymore AT8-positive cell bodies than those injected with clone 1, c
not develop pathology after injection.
(D) P301S mice were inoculated with clone 1, clone 9, or clone 10 lysate. Repres
stacks. Arrowheads in clone 9 CA3 insets highlight an AT8-positive cell body that c
10 CA3 insets each represent a different AT8-positive puncta that is visible in only
CA3 inset and AT8 IF – 25 mm; n = 3–4 per clone). See Figure S4A for MC1 and
(E) Iba1 staining of microglia in CA1 of inoculated P301S mice indicates that only
processes into CA1. See Figure S4C for columns of rod microglia in these anim
animals. See Figure S4E and Figure S4F for data indicating that identical amounof phenotypes associated with single patients suggests a
diversity of patient-derived tau prion strains. Because the cell-
based strain isolation system can likely amplify only a subset
of strains, these data suggest that a disease-associated
ensemble or ‘‘cloud’’ of conformations exists within individual
patients. Nevertheless, certain tauopathies can be differentiated
by their strain composition.
DISCUSSION
Many papers describing ‘‘prion-like’’ behavior of proteins asso-
ciated with neurodegenerative diseases have been published
in the last several years. In the case of tau, fibrils transmit its
aggregated state from the outside to the inside of a cell (Frost
et al., 2009a; Holmes et al., 2013), suggesting that this mecha-
nism could account for the stereotyped progression of tauopa-
thies. This model of disease was subsequently supported in vivo
with reports of trans-synaptic spread of pathology (de Calignon
et al., 2012; Kim et al., 2010; Liu et al., 2012) and protein-only in-
duction of tau inclusions (Iba et al., 2013). Work with other intra-
cellular amyloids (Desplats et al., 2009; Holmes and Diamond,
2012; Mu¨nch et al., 2011; Ren et al., 2009) has suggested that
prion-like transmission can explain the progression of many
neurodegenerative diseases.
Whether or not various noninfectious amyloids are ‘‘true’’
prions has become a contentious subject of debate. Some
define prions as being capable of interorganism transmission
of pathology and by the ability to survive freely in the environ-
ment (Aguzzi and Rajendran, 2009). To date, there exists no ev-
idence that this definition can be applied to proteins other than
PrP. This restrictive definition, based on early research into prion
diseases such as kuru and scrapie, potentially ignores a rich
biology that mechanistically unites many common diseases.
Importantly, we now know that the vast majority of human prion
diseases have noninfectious etiology, and that their great pheno-
typic heterogeneity can be attributed to strains (Collinge and
Clarke, 2007). With respect to prion-like intracellular amyloids
in humans, recent data indicate that homogenates from distinct
tauopathies might reproduce certain pathological features of the
diseases in transgenic mice, which is consistent with strain
behavior (Clavaguera et al., 2013a). Other studies explicitly sug-
gest the existence of a-synuclein strains, based on the produc-
tion of different a-synuclein conformers in vitro (Bousset et al.,
2013; Guo et al., 2013; Sacino et al., 2013). However, to account
for phenotypic diversity at a systems level, a prion strain must
replicate with remarkable reliability for extended periods of
time. A stringent test of this is to ensure that the strain is stable,(CA1 and CA3) of WT and P301S mice. P301S mice injected with clone 9 lysate
lone 10, or RF (error bars represent SEM, * = p < 0.05, ** = p < 0.01).WTmice do
entative whole hippocampus images are shown with the corresponding CA3 z
an be seen throughout both z stack images. The arrow and arrowhead in clone
one z stack plane (scale bars represent hippocampus – 1 mm; CA3 – 100 mm;
X-34 staining, Figure S4B for lack of pathology in inoculated WT mice.
clone 10 induces the formation of rod microglia, which extend highly polarized
als and Figure S4D for absence of these microglia in clone 10-inoculated WT
ts of total and insoluble tau were used in inoculations.
Neuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc. 1279
AB
C
A
3
P301S Clone 1 P301S Clone 10P301S Clone 9
Generation 0
Generation 1
Generation 2
C
A
1
C
A
3
P301S Clone 1 P301S Clone 10P301S Clone 9
C
A
1
C
A
3
P301S Clone 1 P301S Clone 10P301S Clone 9
C
A
1
C
Generation 0 Generation 1 Generation 2Original clones Secondary Clones
P301S Clone 10P301S Clone 9
C
A
3
C
A
1
C
A
3
C
A
1
P301S Clone 10P301S Clone 9
C
A
3
C
A
1
P301S Clone 10P301S Clone 9
Generation 0
Generation 1
Generation 2
21 days 28 days 28 days IP
Figure 5. Tau Strains Passage Stably through Multiple Generations of P301S Mice
(A) Lysates (10 mg protein) were injected bilaterally into the hippocampi of 3-month-old P301S mice (Generation 0/G0). At 21 days postinjection, brains were
collected for histology and homogenization. Hippocampal homogenate (10 mg) was then bilaterally inoculated into a new round of 3-month-old P301S mice
(Generation 1/G1) followed by a 28-day incubation before the process was repeated for a new cohort of 3-month-old P301S mice (Generation 2/G2). At G0 and
(legend continued on next page)
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Tau Prion Strains in Cells, Mice, and Patientsisolatable, and replicates its phenotype through living systems
with high fidelity (Bruce et al., 1994; Prusiner, 1998). Until now,
these characteristics have not been linked to a mammalian pro-
tein other than PrP. Based on these criteria, our data strongly
suggest that tau should be considered a bona fide prion.
Fittingly, we also find that different tauopathies are associated
with different strains. This has direct implications for understand-
ing the phenotypic diversity of tauopathies.
Tau as a Prion in Cell Culture and Mice
We began this work by establishing a monoclonal HEK293 cell
line that stably expresses the tau repeat domain fused to YFP.
In the absence of tau aggregate exposure, these cells propa-
gate only tau RD monomer (‘‘naı¨ve’’ cells). Induction of aggrega-
tion with recombinant fibrils, however, created clonal lines
(clone 9 and clone 10) that indefinitely propagate unique aggre-
gate structures, or strains, from mother to daughter cells. These
strains differ with respect to inclusion morphology, aggregate
size, sedimentation profile, seeding capacity, protease diges-
tion patterns, toxicity, and subcellular localization. Importantly,
these properties are cell-independent, because we recreated
the strains by protein transfer into naive cells. Further-
more, the distinct inclusion morphologies we observed might
represent specific cellular responses to different aggregate con-
formations, consistent with their unique patterns of compart-
mentalization. The cell-culture system established here might
thus prove useful to detect, propagate, and characterize addi-
tional tau prion strains, as well as to understand the cellular
mechanisms that govern strain replication, subcellular localiza-
tion, degradation, and toxicity.
In vivo, we found that strains 9 and 10 induce unique patho-
logical phenotypes in transgenic P301S mice. Moreover, clone
10 lysate uniquely results in the formation of rod-shaped
microglia, which indicates that distinct tau conformers initiate
different physiological responses in vivo. More remarkably, we
report that the morphological phenotypes breed true through
multiple generations of mice, a property that is shared with
PrP. We recognize that pathological phenotypes can be prone
to bias in detection. Thus, we passaged strains back to naive
tau RD-YFP cells, conclusively demonstrating the robust inher-
itance of tau conformations. This data also indicates that the
repeat domain is sufficient to encode strains that are unal-
tered by templating of their structure to FL tau. Therefore, the
reported cell model is useful for detecting and propagating
physiologically relevant tau prion strains. Finally, using unilateral
inoculation of clone 9 lysate, we show that tau aggregation
propagates along known anatomical connections, supporting
conclusions of previous studies (de Calignon et al., 2012; Iba
et al., 2013; Liu et al., 2012). More importantly, however, these
cellular and in vivo studies indicate that a mammalian protein
amyloid other than PrP templates itself with high fidelity through
living systems.G2, hippocampal homogenates were IP (anti-tau 8.5; epitope = aa 25–30; outside
strain inheritance (G0 and G2 clones). For each cohort, n = 3–4 animals.
(B and C) AT8 staining (DAB = B and immunofluorescence = C) reveals that the m
multiple generations of tau P301S mice. See Figure S5A for images of whole h
Figure S5C for data indicating that strain passage is not due to residual tau RD sTau Prion Strains in Human Tauopathy Brains
Knowing that tau acts as a prion in experimental models,
we examined whether this concept could explain phenotypic
diversity observed in tauopathies. Brain samples from three
patients with distinctive tauopathies induced diverse self-prop-
agating tau prion strains in culture. Our initial work with these
strains indicated that inclusion morphology is a reliable surro-
gate for more labor-intensive biochemical characterization.
This led us to assess the morphological phenotypes of tau
strains derived from numerous patients (n = 29) across a
spectrum of tauopathies (AD, AGD, CBD, PiD, PSP). Each of
the diseases was associated with several cellular inclusion
morphologies, although certain diseases (AD, CBD, PiD) are
more homogeneous than others (PSP, AGD). It is noteworthy
that AD pathology is characteristically more uniform than other
tauopathies (Duyckaerts et al., 2009; Feany et al., 1996), and
the tau strains isolated from AD brains were by far the most
homogeneous. The isolation of multiple conformers from indi-
viduals suggests that a tau aggregate ensemble exists within
each person, and that standard methodologies (e.g., histopa-
thology, inoculation into mice, protease digestion) will be insuf-
ficient for a nuanced understanding of this conformational
complexity. Similar to what has been reported for PrP amyloids
(Collinge and Clarke, 2007; Li et al., 2010), we speculate that
these clouds of tau conformers are prone to selective pres-
sures at the cellular level, which might have implications
for therapies that target extracellular tau (Holmes et al., 2013;
Yanamandra et al., 2013).
Although we have now succeeded in categorizing multiple
distinct strains, the cell-based isolation method can only detect
those that successfully template to tau RD-YFP and propagate
without overt cellular toxicity. The inability to reselect clone 9
derivatives in the Tet Off background illustrates this problem.
On the other extreme, strains that do not propagate with high
fidelity might be lost prior to clonal selection. For example,
the strains present in several AGD and PiD samples were not
stable in cell culture, making detailed characterization of these
strains difficult with our model system. Furthermore, it is likely
that seeding barriers between tau from patient brain (consisting
of various tau isoforms and posttranslationally modified spe-
cies) and tau RD in cell-culture limits the strains we can detect.
Our observation of an asymmetric seeding barrier between
P301 mutants and WT tau underscores this limitation, as does
recent work indicating similar barriers between three-repeat
(3R) and four-repeat (4R) tau (Dinkel et al., 2011). Despite
some limitations, the model system presented here has many
advantages over standard animal inoculations, because it is
less resource-intensive and can parse multiple conformations
from a single isolate. Finally, knowledge of the existence of
multiple strains in vivo might allow us to characterize them on
molecular terms and diagnose patients with much greater pre-
cision, possibly by determining structures and conformationalRD region) and inoculated into the original tau RD-YFP line to test the fidelity of
orphological phenotypes of phosphorylated tau inclusions breed true through
ippocampi, Figure S5B for images of clone 1 AT8 immunofluorescence, and
eeds remaining in diluted inoculate.
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Figure 6. Strains Transfer Faithfully to Cell Culture after Passage through Generation 0 and Generation 2 Mice
(A) IP material was transduced into tau RD-YFP cells prior to passage onto coverslips. At 96 hr, cells were fixed. Only clone 9-, clone 10-, and RF-inoculated mice
seed inclusions robustly. WT mouse homogenates never seed aggregation. Ten fields, each with 100+ cells, were analyzed per brain, and averages were
collapsed within cohorts (error bars represent SEM, **** = p < 0.0001). See also Figure S6A for split-luciferase complementation data.
(B) Inclusion morphologies are maintained following passage through P301S mice (G0). IP FL tau from individual P301S mice inoculated with clone 9 or clone 10
was transduced into tau RD-YFP cells, and a single representative clone per mouse was isolated and amplified. All G0-derived clones continue to propagate
the original phenotypes. See also Figures S6B and S6C for quantification of colony morphologies prior to monoclonal cell line isolation and Figure S6D for
quantification of total IP tau used in G0 experiments.
(legend continued on next page)
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Tau Prion Strains in Cells, Mice, and Patientsepitopes specific to individual diseases. This could help facili-
tate therapeutic strategies tailored toward the underlying pro-
tein pathology.
Expanding the Spectrum of Prion Diseases
Our data, along with cell-culture (Holmes and Diamond,
2012), pathological (Clavaguera et al., 2013b), and imaging
(Greicius and Kimmel, 2012) studies are consistent with the
model of cell-cell ‘‘transmission’’ of neurodegenerative diseases
throughout the nervous system. Our finding ofmultiple self-prop-
agating conformations in experimental and patient-derived tau
preparations suggests that tau should be defined as a prion,
because it encodes self-catalyzing conformational information
that it propagates indefinitely with high fidelity. Importantly, how-
ever, there is no evidence to suggest that ADor other tauopathies
are infectious in the classical sense, as they are not known to be
communicable between individuals. The infectious property of
PrPScmight reflect its anomalous biochemical stability or expres-
sion profile, whereas a host of other cell biological and biophys-
ical properties, especially the ability to encode self-propagating
conformers, will more appropriately unify the growing family of
‘‘prion-like’’ proteins. Indeed, the vast majority (>95%) of human
prion disease cases appear to be genetic or sporadic, indicating
that infectivity should not be a restrictive criterion.Wepredict that
strains associated with distinct clinical phenotypes will also be
identified for synucleinopathies and ALS/FTLD spectrum disor-
ders, both of which feature diversity in pathological presentation
(Halliday et al., 2011; Van Langenhove et al., 2012). Understand-
ing disparate amyloid neurodegenerative diseases in light of this
model should create new possibilities for common diagnostic
and therapeutic approaches.
EXPERIMENTAL PROCEDURES
Statistical Analysis
Unless explicitly stated, all statistical analyses used one-way analysis of vari-
ance with Bonferroni’s multiple comparison test.
Liposome-Mediated Transduction of Fibrils, Lysate, Brain
Homogenate
Cell lines were plated at 250,000 cells per well in 12-well plates. Twenty-four hr
later, fibrils or lysate were combined with OptiMEM (GIBCO) to a final volume(C) Limited proteolysis reveals that G0 clones feature similar banding patterns
10–13 kDa (versus smear for G0-clone 9) and a band between 20 and 25 kDa th
(D) Split-luciferase complementation demonstrates similar seeding efficiencies
experiments are shown, each read in quadruplicate at 48 hr posttransduction of
(E) IP material from pooled G2 mice was transduced into naive tau RD-YFP cells p
formation is significantly greater for G2-clone 9 and G2-clone 10 mice than G2-clo
Seeding is specific to tau because IgG-precipitated material never seeds. Ten fi
SEM, * = p < 0.05, **** = p < 0.0001). See also Figure S6E for split-luciferase com
(F) Inclusion morphologies are maintained following passage through three gener
into tau RD-YFP cells, and 12 clones per cohort were isolated. Representative exa
digestion patterns and seeding ratios to each other, which are unique from all 22
monoclonal cell line isolation and Figure S6G for images of all 24 clones.
(G) Limited proteolysis reveals that G2 clones feature similar banding patterns to
(versus smear for G2-clone 9) and a band between 20 and 25 kDa that is slightly s
are unique in featuring bands at 15 and 25 kDa.
(H) Split-luciferase complementation demonstrates similar seeding efficiencies
across clones, each of which was read in quadruplicate at 48 hr posttransductio
outlier clones (9G and 10D), which also feature unique inclusion morphologies aof 100 mL. 96 ml OptiMEM and 4 ml lipofectamine-2000 (Invitrogen) was then
added to a final volume of 200 mL. After 20 min, liposome preparations were
added to cells. Eighteen hr later, cells were replated in wells of a 6-well plate.
For more details, see Supplemental Experimental Procedures.
Semidenaturing Detergent Agarose Gel Electrophoresis
SDD-AGE was performed as previously described (Kryndushkin et al., 2003)
with minor modifications. Cell pellets lysed in 0.05% Triton X were clarified
by sequential centrifugations (500 3 g, 1000 3 g). Low-SDS 1.5% agarose
gels were prepared by dissolving agarose in buffer G (20 mM Tris-Base,
200 mM glycine, in ddH2O) with 0.02% SDS. For each condition, 5 mg of
clarified cell lysate was incubated with 0.02% SDS sample buffer for 7 min
prior to loading. SDD-AGE was run in Laemmli buffer (Buffer G with 0.1%
SDS). Protein was transferred to Immobilin P (Millipore). Membranes were
probed for tau with rabbit polyclonal anti-tau ab64193 (1:4000, AbCam) and
counter-probed with goat anti-rabbit HRP (1:4,000, Jackson Immunotherapy).
For more details, see Supplemental Experimental Procedures.
Sedimentation Analysis
Clarified cell lysate was centrifuged at 100,000 3 g for 1 hr. Supernatant was
placed aside and the pellet was washed with 1.5 ml PBS prior to ultracentrifu-
gation at 100,0003 g for 30min. The supernatant was aspirated and the pellet
was resuspended by boiling in RIPA buffer with 4% SDS and 100 mM DTT.
Bradford assay (Bio-Rad) with BSA standard curve was used to normalize
all protein concentrations. Samples were run on 4%–15% SDS-PAGE gels
(Bio-Rad) and protein was transferred to Immobilin P (Millipore). Membranes
were probed for tau as described above. For more details, see Supplemental
Experimental Procedures.
Split-Luciferase Complementation Assay
Polyclonal HEK293 cells stably expressing tau RD-Cluc and tau RD-Nluc
were plated at 240,000 cells per well in 12-well plates 24 hr prior to cell lysate
transduction. Clarified cell lysate was prepared as described above. Cell
lysate (20 mg in 10 mL volume) was diluted with 90 ml OptiMEM (GIBCO)
and incubated with 96 ml OptiMEM and 4 ml lipofectamine-2000 (Invitrogen)
for 20 min. Liposome preparations were then added to cells and 18 hr later,
cells were replated in quadruplicate in a 96-well plate. Twenty-four hr later,
media was aspirated from wells and replaced with luciferin solution
(150 mg/mL D-luciferin potassium salt, Gold Biosciences, in Dulbecco’s
phosphate-buffered saline, GIBCO). Cells were incubated with luciferin solu-
tion for 3 min at 37C prior to reading luminescence with a Tecan M1000
fluorescence plate reader. For more details, see Supplemental Experimental
Procedures.
Protease Digestion
Pronase (Roche) was diluted in PBS to a final concentration of 1 mg/mL and
single-use aliquots were stored at 80C. Clarified cell lysate was preparedto the original parental lines, with G0-clone 10 featuring a doublet between
at is slightly smaller than G0-clone 9 bands.
in G0 clones relative to original parental lines. Averages of four separate
lysate (error bars represent SEM, **** = p < 0.0001).
rior to passage onto coverslips. At 96 hr, cells were fixed. Seeding of inclusion
ne 1 mice. G2-clone 1 tau induces inclusions on rare occasions (1% of cells).
elds, each with 150+ cells, were analyzed per condition (error bars represent
plementation data.
ations of mice. IP full-length tau from pooled G2 homogenates was transduced
mples are shown. The two clones boxed in red feature similar limited proteolysis
other clones. See Figure S6F for quantification of colony morphologies prior to
their parental lines, with G2-clone 10 featuring a doublet between 10–13 kDa
maller than G2-clone 9 digests. Two clones (boxed in red), one for each cohort,
in G2 clones relative to original parental lines. Seeding ratios were averaged
n of lysate (error bars represent SEM, **** = p < 0.0001). Boxed in red are two
nd limited proteolysis digestion patterns.
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Figure 7. Anterograde and Retrograde Spread of Pathology to Synaptically Connected Regions in Generation 3-clone 9 Mice
(A) Schematic of known projections to and from the hippocampus (DG, dentate gyrus; MEC/LEC, medial and lateral entorhinal cortices; MF, mossy fibers; RSp,
retrosplenial cortex; Sub, subiculum).
(B) Representative images of AT8 staining in the hippocampi of G3 mice inoculated with 10 mg of G2 brain homogenate. Spread of clone 9 pathology to the
contralateral hippocampus is evident. See Figure S7A for whole brain slices.
(C) Summary of pathology present in G3-clone 9 mice. Gradient represents semiquantitative analysis of neurofibrillary tangle-like AT8 cell body positivity
observed in each region (PPA, posterior parietal association area) both 2.5 and 3.0 mm posterior to bregma.
(D) AT8 histopathology observed in brain regions with known projections to and from the hippocampus. Ipsilateral AT8 pathology is observed in the EC and
appears in cortical layers II-III, whereas contralateral pathology is observed in deeper layers of the EC. Pathology is also observed in the retrosplenial cortex,
especially ipsilateral to the injection site. See Figure S7B for subiculum and dentate gyrus images.
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Figure 8. Diverse Tau Prion Strains within Patients and across Diseases
(A) Schematic illustrating methods used to generate patient-derived tau RD prion strains in a monoclonal Tet Off-tau RD-YFP line. See Figure S8 for data
indicating that different inclusion morphologies are associated with different biochemical and seeding properties.
(B) Morphological phenotypes associated with tau RD prion strains induced by patient material: no seeding, toxic, mosaic, ordered, disordered, speckles.
Representative examples are shown.
(C) IP tau from 29 patient samples (AD, Alzheimer’s disease; AGD, argyrophilic grain disease; CBD, corticobasal degeneration; PiD, Pick’s disease; PSP, pro-
gressive supranuclear palsy) was transduced into tau RD-YFP cells (Tet Off) and as many inclusion-positive clones as could be identified for each patient sample
were blindly picked and amplified. Once confluent in 10 cm dishes, morphological phenotypes were scored by a separate blinded experimenter. See Table S2 for
numerical values, patient-related information, and tissue origin.
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normalized to 1.7 mg/mL. 17 mg (10 mL) of cell lysate was added to 10 ml
of pronase at a concentration of 100 mg/mL (diluted in PBS) for a final
volume of 20 mL. Cell lysates were digested at 37C for one hour. Reactions
were quenched by addition of 20 ml 23 sample buffer (final SDS con-
centration of 1%) and boiling for 5 min. Each sample (15 ml) was run on a
10% Bis-Tris NuPAGE gel (Novex by Life Technologies) and protein was
transferred to Immobilin P (Millipore). Membranes were probed for tau
as described above. For more details, see Supplemental Experimental
Procedures.
Animals and Hippocampal Injections
Transgenic mice expressing FL human tau 4R1N P301S under the murine
prion promoter (Yoshiyama et al., 2007) were maintained on a B6C3 back-
ground. P301S and nontransgenic littermates were anesthetized with isoflur-
ane and were bilaterally injected into the hippocampus (from bregma:
2.5 mm posterior, ±2 mm lateral, 1.8 mm ventral) with either 2 ml of5 mg/mL clarified lysate/homogenate or 2 ml of 2.5 mg/mL recombinant tau
RD fibrils as previously described (DeVos and Miller, 2013). For all experi-
ments, conditions were gender-matched (Table S1). Unilateral injections
were used for G3 spread experiments. All protocols involving animal use
were approved by the institutional animal care and use committee at Wash-
ington University in St. Louis. For more details, see Supplemental Experi-
mental Procedures.
Histology and Immunohistochemistry
Sections (50 mm) were taken through the entire left hemisphere with a freezing
microtome. For DAB stains, brain slices were incubated with indicated anti-
bodies overnight at 4C. Slices were then counter-stainedwith the appropriate
secondary. Slices were then incubated at room temperature for 30minwith the
VECTASTAIN Elite ABC Kit (Vector Labs), followed by DAB development with
the DAB Peroxidase Substrate Kit with the optional nickel addition (Vector
Labs). Histological images and z stacks were captured with the Olympus
Nanozoomer 2.0-HT (Hamamatsu) and analyzed with the NDP viewer softwareNeuron 82, 1271–1288, June 18, 2014 ª2014 Elsevier Inc. 1285
Neuron
Tau Prion Strains in Cells, Mice, and Patients(Hamamatsu). For immunofluorescence stains, slices were incubated in block-
ing solution with indicated primary antibody overnight at 4C, followed by
appropriate secondary labeling. For more details, see Supplemental Experi-
mental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.04.047.
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